Cost-effectiveness analysis of antiemetic regimen containing aprepitant as first-line prophylaxis for high dose cisplatin-based chemotherapy induced emesis: a single institution study in Taiwan
- At: 2013 FIP Congress in Dublin (Ireland)
- Type: Poster
- By: CHIEN, Shu-Chen (Taipei Medical University Hospital, Department of Pharmacy, Taipei, China Taiwan)
- Co-author(s): Chen, Bi-Li (Taipei Medical University Hospital, Taipei, China Taiwan)
Kok, Chin Yee (Taipei Medical University Hospital, Taipei, China Taiwan)
Background: Aprepitant in combination with serotonin receptor antagonist and corticosteroid provide superior protection over chemotherapy-induced nausea and vomiting (CINV). Under limited budget within a universal health insurance system in Taiwan, cost-effectiveness of antiemetic regimen containing aprepitant with higher cost have to be.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.